Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Other Non-Current Assets (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Other Non-Current Assets for 13 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $1.1 million, changed 0.0% over the prior year.
  • Other Non-Current Assets was $1.1 million for Q4 2025 at Abvc Biopharma, up from $117017.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $6.7 million in Q4 2023 and bottomed at $39977.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $702771.7, with a median of $135135.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets surged 4864.0% in 2023, then tumbled 83.23% in 2024.
  • Year by year, Other Non-Current Assets stood at $41157.0 in 2021, then soared by 228.34% to $135135.0 in 2022, then soared by 4864.0% to $6.7 million in 2023, then crashed by 83.23% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ABVC at $1.1 million in Q4 2025, $117017.0 in Q3 2025, and $691900.0 in Q2 2025.